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1. Introduction 
The excipients used during manufacturing as well as the quality of the pharmaceutical 
product development and preparation are of great importance to dosage form performance. 
A continuous know-how improvement of both formulation and production process 
parameters with respect to drug release profiles is a basic aspect of the quality framework 
for pharmaceutical products. Drug release/dissolution studies from solid dosage forms can 
be considered among as the most investigated topics in pharmaceutical research (De Castro 
et al., 2006; Macheras & Iliadis, 2006; Siepmann & Siepmann, 2008). Such a background 
becomes of paramount relevance in the case of insoluble or poorly soluble drugs, where 
dissolution represents the most critical factor affecting the rate of systemic absorption, 
especially in the presence of polymorphism (Snider et al., 2004). Moreover, apart from 
representing an important element in development and quality control in drug research, 
dissolution test is proposed to be a surrogate for drug bioavailability evaluation. In fact, in 
vivo-in vitro relationship represents a useful tool to answer the question about the 
interchangeability of generic and branded products by revealing differences in dissolution 
kinetics (Dressmann & Reppas, 2010; Hlinak et al., 2006). In order to increase predictability 
of these results, several attempts to make in vitro test conditions closer to the physiological 
ones have been made, for example by adjusting pH or by adding surfactants. However, the 
so-called “sink conditions” (based on bulk drug solubility i.e. in a system where the solute is 
present for more than 15% of its maximum solubility have been studied), obtained by using 
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a high concentration of a surfactant in the dissolution medium, may not be a proper 
approach in developing a bio-relevant dissolution method for a poorly water-soluble drugs 
(Sirisuth et al. 2002; Tang et al., 2001; Jamzad & Fassihi, 2006). “Non-sink conditions” 
represented a very discriminating dissolution conditions, acting as a sort of magnifier lens 
for an in-depth evaluation of the dissolution phenomenology, and dissolution tests under 
non-sink conditions can be a predictive tool during formulation development as well as for 
batch-to-batch quality control (Siewert et al., 2003). 
2. Dissolution testing in pharmacopeia 
The methods of in vitro dissolution testing can be traced to two general categories: “stirrer 
beaker method” and “flow through procedure”.  
From a regulatory standpoint, the legally-binding documents to carry out the dissolution 
tests are reported in the 7th edition of European Pharmacopoeia (EP), the 34 United States 
Pharmacopoeia (USP), and the 15th edition of Japanese Pharmacopoeia (JP). The World 
Health Organization (WHO) provides in the 4th edition of International Pharmacopoeia 
(IntPh) a more global coverage of issues and strives towards harmonisation among world 
pharmacopoeia guidance and source material. 
The various texts are comparable to the general notions, but differ in the apparatuses 
described: EP with “Dissolution test for solid dosage forms” (Council of Europe, 2011) and 
USP with “Dissolution” (United States Convention, 2011a) show four apparatuses: 1 (for 
Basket method); 2 (for paddle method), 3 (Reciprocating cylinder) and 4 (Flow-through cell), 
the latter being lacking in the JP “Dissolution test” (Society of Japanese Pharmacopoeia, 
2007) monograph. On the other hand, in the IntPh “Dissolution test for solid oral dosage 
forms” section (World Health Organization, 2011), only the first two devices are indicated. 
In Table 1, the relation between the dimensions for the first three devices is shown: all the 
measures are equivalent, and any differences can be noticed only by IntPh, mainly in terms 
of the significant digits. 
Even the choice of the dissolution medium is almost completely overlapped between EP and 
USP, with a variety of buffers at various pH (e.g. phosphate, acetate, TRIS). Besides, the JP 
refers to the monographs of specific formulations, but ranging over various possibilities, 
from pure water to the various buffers. On the other hand, the IntPh indicates eight different 
points for different pHs of the dissolution media, including simulated gastric fluid (SGF, pH 
1.2) and simulated intestinal fluid (SIF); worthy of note is the pH differences of the latter: 7.5 
for IntPh vs. 6.8 for both EP and USP.  
Moreover, in the latest edition of the EP, as well as in the USP section “The dissolution 
procedure: development and validation” (United States Convention, 2011b), a chapter 
entitled “Recommendations on methods for dosage forms testing” (Council of Europe, 
2010a) is given, suggesting the use of sink-condition. Sink conditions normally occur in a 
volume of dissolution medium that is at least 5-10 times the saturation volume, usually by 
adding surfactants. However, such an approach may be inappropriate in developing a bio-
relevant dissolution method for a poorly water-soluble drug (Sirisuth et al. 2002; Tang et al., 
2001; Jamzad & Fassihi, 2006). 
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Item EP 7th USP 34 JP 15th IntPh 3rd 
Vessel 
Height 
Internal diameter 
 
160-210 
98-106 
 
160-210 
98-106 
 
160-210 
98-106 
 
168±8 
102±4 
Basket 
Shaft Diameter 
 
Screen 
Wire thickness 
Openings 
Height of screen 
Total height of basket 
Internal diam. of basket 
External diam. of basket 
External diam. of ring 
Vent hole diameter 
Height of coupling disk 
 
6.4±0.1 or 
9.75±0.35 
 
0.22-0.31 
0.36-0.44 
27.0±1 
37±3 
20.2±1 
22.2±1 
25.0±3 
2.0±0.5 
5.1±0.5 
 
6.3-6.5 or 
9.4-10.1 
 
0.25-0.31 
0.36-0.44 
27.0±1.0 
37.0±3.0 
20.2±1.0 
22.2±1.0 
25.0±3.0 
2.0±0.5 
5.1±0.5 
 
6.3-6.5 or 
9.4-10.1 
 
0.25-0.31 
0.36-0.44 
27.0±1 
37±3 
20.2±1 
22.2±1 
25.0±3 
2.0±0.5 
5.1±0.5 
 
6.4±0.1 or 
9.75±0.35 
 
0.254 
0.381 
27.0±1 
36.8±3 
20.2±1 
22.2±1 
25.4±3 
2 
5.1±0.5 
Position of the stirring 
device 
Distance from the bottom 
Distance between shaft axis 
and vertical axis of the 
vessel 
25±2 
≤2 
25±2 
≤2 
25±2 
≤2 
25±2 
≤2 
Stirring characteristics 
Smoothly 
without 
significant 
wobble 
Smoothly 
without 
significant 
wobble 
Smoothly 
without 
significant 
wobble 
Ensure there is no 
significant wobble 
on any rotating 
shaft 
Paddle 
Shaft Diameter 
 
Blade 
Upper chord 
Lower chord 
Height 
Radius (disk) 
Radius (upper corners) 
Thickness 
 
9.4-10.1 
 
 
74.5±0.5 
42 
19.0±0.5 
41.5 
1.2±0.2 
4.0±1.0 
 
9.4-10.1 
 
 
74.0-75.0 
42.0 
19.0±0.5 
41.5 
1.2±0.2 
4.0±1.0 
 
9.4-10.1 
 
 
74.0-75.0 
42.0 
19.0±0.5 
41.5 
1.2±0.2 
4.0±1.0 
 
9.75±0.35 
 
 
74.5±0.35 
42.0±1 
19.0±1 
41.5 
- 
4.0±1 
Position of the stirring 
device 
Distance from the bottom 
Distance between shaft axis 
and vertical axis of the 
vessel 
25±2 
≤2 
25±2 
≤2 
25±2 
≤2 
25±2 
≤2 
Stirring characteristics 
Smoothly 
without 
significant 
wobble 
Smoothly 
without 
significant 
wobble 
Smoothly 
without 
significant 
wobble 
Ensure there is no 
significant wobble 
on any rotating 
shaft 
Table 1. Dissolution Apparatuses. Dimensions (mm) of the vessel, basket and paddle.  
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3. Nimesulide 
Nimesulide (NIM) is a non-steroidal anti-inflammatory drug, selective COX-2 inhibitor with 
analgesic and antipyretic properties (Martindale, 2009). IUPAC nomenclature is N-(4-Nitro-
2-phenoxyphenyl)methanesulfonamide, with empirical formula C13H12N2O5S (MW=308.31) 
and CAS number 51803-78-2 (Scheme 1). NIM monograph is present only in the EP (Council 
of Europe, 2010b). 
 
Scheme 1. Chemical structure of NIM 
Its approved indications are the treatment of acute pain, the symptomatic treatment of 
osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. 
NIM was discovered in 1971 in the U.S. by George G.I. Moore at Riker Laboratories (later 
acquired by 3M Co.), but in 1980 NIM was licensed by Helsinn Healthcare SA 
(Switzerland) who proceeded to invest in extensive investigations on the drug (Rainsford, 
2006). It was launched in Italy for the first time as Aulin® in 1985 (Consalvo et al., 2010) 
and is currently available in more than 50 countries worldwide, among others France, 
Portugal, Greece, Switzerland, Belgium, Mexico and Brazil. NIM has never been filed for 
Food and Drug Administration (FDA) evaluation in the United States, where it is not 
marketed (Traversa et al., 2003) 
After the expiry of patent protection, a number of other companies have started production 
and marketing of NIM products. 
Controversy regarding NIM toxicity persists due to the fact that clinical series reports and 
epidemiological trials continue to involve NIM in severe liver damage during the post-
marketing studies (Bessone, 2010). Briefly, on August 1, 2003 the Committee for 
Proprietary Medicinal Products (CPMP) of the European Medicines Agency (EMA) 
reported that the benefit/risk profile of NIM containing medicinal products (e.g. Aulin, 
Mesulide, Nimed and associated product names) for systemic and topical use is 
favourable and that Marketing Authorisations should be maintained/granted. The CPMP 
recommended to restrict the use of NIM to the indications of treatment of acute pain, 
symptomatic treatment of painful osteoarthritis and primary dysmenorrhoea for the 
systemic formulations and symptomatic relief of pain associated with sprains and acute 
tendinitis for the topical formulation (EMEA, 2003). 
The Irish Medicines Board (IMB) announced the suspension of NIM from the Irish market 
and reported it to the EU Committee for Human Medicinal Products (CHMP) for a review 
of its benefit/risk profile. The decision is due to the reporting of six cases of potentially 
related liver failures to the IMB by the National Liver Transplant Unit, St Vincent Hospital. 
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These cases occurred in the period from 1999 to 2006 (IMB, 2007). On December 3, 2007 
Ireland's RTÉ aired an investigative programme highlighting the deadly side effects of NIM 
and how it has been linked to over 300 cases of liver disease throughout Europe. 
On September 21, 2007 the EMA released a press release on their review on the liver-related 
safety of NIM. The EMA has concluded that the benefits of these medicines outweigh their 
risks, but that there is a need to limit the duration of use to ensure that the risk of patients 
developing liver problems is kept to a minimum. Therefore the EMA has limited the use of 
systemic formulations (tablets, solutions, suppositories) of NIM-containing medicinal products 
to 15 days because of reports of severe hepatic adverse reactions (EMA, 2007; Li et al., 2009). 
Singapore Health Science Authority (HSA) suspended NIM containing drugs in June 2007 
(Singapore News, 2007; HSA, 2007). Several reports have been made of adverse drug 
reactions in India (Khan & Rahman, 2004a, 2004b; Rahman & Khan, 2004). On Feb 12, 2011, 
Express India reported that the Union Ministry of Health and Family Welfare had finally 
decided to ban the pediatric use of the analgesic, NIM suspension. From 2011 onwards, it 
has been totally banned in India. 
NIM chemico-physical properties could be summarised as: i) weak acid properties (pKa 
reported ranging between 5.9 and 6.56 (Singh et al., 1999; Singh et al., 2001; Dellis et al., 
2007); ii) values of octanol-water partition coefficient (log P) of 2.38 (Singh et al., 2001); iii) 
practically insoluble in water (10 Ǎg/mL) (Piel et al. 1997); iv) according to the 
Biopharmaceutical Classification System, BCS, (FDA, 2000), NIM can be classified as a class 
II drug (low solubility and high permeability), therefore, the drug dissolution may be a rate-
limiting step in the drug adsorption process. 
Previous studies were carried out for both in vitro (Butler et al., 2000; Rădulescu et al., 2010) 
and in vivo comparisons among NIM-containing tablets (Hutt et al. 2001; Ilic et al. 2009). 
However, in the former only a small number of commercial preparations were investigated 
under sink-condition by means of abnormal surfactant concentration (Butler et al. 2000), and 
the release rate seems to be critically influenced not by pH value or the concentration of 
endogenous surfactant, but by the combination of the two characteristics of the in vitro 
dissolution media (Rădulescu et al., 2010), while in the latter no in vitro and in vivo 
correlation (IVIVC) was investigated. Moreover, since due to different crystallization 
processes, crystallographic modification has been recently reported (Kapoor et al. 1998; Di 
Martino et al. 2007; Moneghini et al. 2007), even though only a single crystal structure has 
been identified (Dupont et al., 1995). Thus, information on the influence of the different 
nature and/or amount of excipients as well as of the adopted technological parameters on 
the in vitro drug release characteristics are reputed of interest. 
4. Materials and methods 
4.1 Dosage form selection 
Ten multisource IR NIM tablet formulations (RF for reference formulation, MSF for the 
multiple-source product formulation, and BF1-BF8 for non-branded bioequivalent 
formulations) were obtained from the Italian market. They all nominally contain 100 mg of 
the active ingredient, but greatly differ with respect to the excipient composition. Table 2 
summarizes the qualitative excipient composition of the various NIM tablets. 
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Auxiliary Substances RF MSF BF1 BF2 BF3 BF4 BF5 BF6 BF7 BF8 
Hydroxypropyl cellulose X X X X X   X   
Lactose X  X X X X X X X* X 
Cellulose, microcrystalline X X X X X X X X† X X 
Castor oil, hydrogenate X X X X X     X 
Magnesium stearate X X X X X X X X X X 
Sodium docusate X X X X X  X    
Sodium starch glycolate X X X X X   X X X 
Maize starch      X X    
Sodium dodecyl sulphate      X X  X  
Glyceryl behenate      X‡ X    
PEG§          X 
Talc         X  
*explicitly reported as Lactose monohydrate; †reported as microgranular; ‡referred as Compritol 888; §no 
more info are reported 
Table 2. Qualitative excipient composition of the various NIM tablets. 
4.2 Tablet appearance 
Each tablet was visually examined for shape and any evidence of physical differences such 
as weight, thickness and dimension was recorded. 
4.3 Calibration curve 
Calibration curve for NIM reference standard (RS) was obtained by measuring the UV 
absorption (Perkin Elmer L25 spectrophotometer, ǌmax: 392.6 nm) in dissolution medium 
(Simulated Intestinal Fluid, SIF, pH 6.8) prepared according to EP (Council of Europe, 
2010a) except for the absence of pancreatin, in conformity with the aim of this study. This 
pH value was selected because of the NIM negligible dissolution in acidic conditions. Due to 
the low aqueous NIM solubility, NIM stock solution was prepared by accurate weight of the 
substance and subsequent dissolution in 5 mL of ethanol, submitting to ultrasound in a 
sonicator bath for five minutes, and then diluted to a final volume of 100 mL with SIF, 
corresponding to 50 Ǎg/mL of NIM. Calibration samples were prepared from three 
separately weighed stock solutions to obtain sample solutions containing scalar 
concentrations of NIM. Samples were stored at +4 °C until analysis. The linearity of the 
calibration curves was confirmed over the range 1-20 Ǎg/mL. 
4.4 Solubility studies 
Apparent solubility (Sapp) referring to the dynamic solubility (Mosharraf & Nystrom, 2003) of 
both NIM RS and NIM tablets were determined by stirring an excess amount of the samples in 
250 mL of SIF, on a multistirrer thermostatted at 37 ± 0.5 °C for a suitable time in order to 
achieve equilibrium (max 72 hours). Twenty tablets of the same commercial product were 
weighed and powdered (particle size ≤ 150 µm, by sieving). An amount corresponding to one-
fourth of a tablet (equivalent to 25 mg of NIM) was weighed and suspended in 250 mL 
dissolution medium. In such a way the ratio among active agent, excipients and volume agrees 
with dissolution studies conditions (see below). The samples were filtered with a 0.45 Ǎm 
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nylon membrane filter (Whatman, Maidstone, UK) and the absorbance of the filtrate was 
measured by UV. Temperature (37 ± 0.5 °C) was carefully maintained constant during all the 
operations and the amount of drug dissolved was calculated using the calibration curve (see 
above). All solubility determinations were performed in triplicate. 
4.5 Dissolution studies 
For tablet dissolution tests, apparatus I (rotating basket method) (Council of Europe, 2011) 
was used employing 1000 mL of SIF at a temperature of 37 ± 0.5 °C and a rotational speed of 
100 rpm. Sample solution (5 mL) was withdrawn at appropriated time intervals (5, 10, 15, 
30, 45 and 60 min) and the drawn volume was replaced with the same amount of blank 
dissolution medium from a separate vessel, also held at a temperature of 37 ± 0.5 °C. The 
samples were filtered with a 0.45 Ǎm nylon membrane filter (Whatman, Maidstone, UK) and 
the absorbance of the filtrate was measured by UV. The amount of NIM was calculated 
through the calibration curve. All the dissolution tests were conducted on twelve tablets for 
each formulation. 
4.6 Mathematical dissolution models 
The data obtained from dissolution studies were analyzed using various mathematical 
models (Table 3), as reported in DDSolver. It is a specialized, freely available software 
program developed by Zhang et al. with the main objective to provide a tool for facilitating 
the parameter calculations in dissolution data analysis using nonlinear optimization model-
dependent approaches (Zhang et al., 2010). In the present chapter, the selection of the 
models for fitting dissolution data has been based on their theoretical applicability.  
 
Dissolution model Equationa 
First-orderb,c 1max (1 )
k tF F e     
Higuchid 0.5HF k t   
Korsmeyer-Peppase nKPF k t   
Hixson-Crowellf 3100 [1 (1 ) ]HCF k t      
Hopfenbergg 100 [1 (1 ) ]nHBF k t      
Baker-Lonsdaleh 
2
33
1 1
2 100 100 BL
F F
k t
            
 
Makoid-Banakari n k tMBF k t e
     
Peppas-Sahlin 1l 21 2
m mF k t k t     
Peppas-Sahlin 2m 0.51 2F k t k t     
Quadraticn 21 2100 ( )F k t k t      
Weibull 1o,p 
( )
100 1
it T
F e


      
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Weibull 2o 100 1
t
F e


      
 
Weibull 3c,o max 1
t
F F e


      
 
Weibull 4c,o,p 
( )
max 1
it T
F F e


      
 
Logistic 1q 
log( )
100
1 log( )
e t
F
e t




       
Logistic 2c,q max
log( )
1 log( )
e t
F F
e t




       
Logistic 3c,r max ( )
1
1 k t
F F
e   
    
Gompertz 1s log( )100
teF e
     
Gompertz 2c,s 
log( )
max
teF F e
     
Gompertz 3c,t 
( )
max
k teF F e
     
Gompertz 4c,u max
k teF F e 
     
Probit 1v  100 log( )F t      
Probit 2c,v  max log( )F F t      
Table 3. Applied dissolution methods. 
aIn all models. F is the concentration (µg/mL) of the drug release in time t. 
bk1 is the first-order release constant. 
cFmax is the maximum fraction of the drug released at infinite time 
dkH is the Higuchi release constant 
ekKP is the release constant incorporating structural and geometric characteristics of the drug-dosage 
form; n is the diffusional exponent indicating the drug-release mechanism 
fkHC is the release constant in Hixson–Crowell model 
gkHB is the combined constant in Hopfenberg model, kHB=k0/(C0×a0), where k0 is the erosion rate 
constant, C0 is the initial concentration of drug in the matrix, and a0 is the initial radius for a sphere or 
cylinder or the half thickness for a slab; n is 1, 2, and 3 for a slab, cylinder, and sphere, respectively 
hkBL is the combined constant in Baker–Lonsdale model, kBL=[3×D×Cs/(r02 ×C0)], where D is the diffusion 
coefficient, Cs is the saturation solubility, r0 is the initial radius for a sphere or cylinder or the half-
thickness for a slab, and C0 is the initial drug loading in the matrix 
ikMB, n, and k are empirical parameters in Makoid–Banakar model (kMB, n, k>0) 
lk1 is the constant related to the Fickian kinetics; k2 is the constant related to Case-II relaxation kinetics; 
m is the diffusional exponent for a device of any geometric shape which inhibits controlled release 
mk1 is the constant denoting the relative contribution of t0.5-dependent drug diffusion to drug release; k2 
is the constant denoting the relative contribution of t-dependent polymer relaxation to drug release 
nk1 is the constant in Quadratic model denoting the relative contribution of t2-dependent drug release; k2 
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is the constant in Quadratic model denoting the relative contribution of t-dependent drug release 
oǂ is the scale parameter which defines the time scale of the process; ǃ is the shape parameter which 
characterizes the curve as either exponential (ǃ=1; case 1), sigmoid, S-shaped, with upward curvature 
followed by a turning point (ǃ>1; case 2), or parabolic, with a higher initial slope and after that 
consistent with the exponential (ǃ<1; case 3) 
pTi is the location parameter which represents the lag time before the onset of the dissolution or release 
process and in most cases will be near zero 
qǂ is the scale factor in Logistic 1 and 2 models; ǃ is the shape factor in Logistic 1 and 2 models 
rk is the shape factor in Logistic 3 model; Ǆ is the time at which F = Fmax/2 
sǂ is the scale factor in Gompertz 1 and 2 models; ǃ is the shape factor in Gompertz 1 and 2 models 
tk is the shape factor in Gompertz 3 model; Ǆ is the time at which F = Fmax/exp(1)≈0.368×Fmax 
uǃ is the scale factor in Gompertz 4 model; k is the shape factor in Gompertz 4 model 
vФ is the standard normal distribution; ǂ is the scale factor in Probit model; ǃ is the shape factor in 
Probit model 
4.7 Statistical analysis 
Results were expressed as the mean ± SD of at least six independent measurements. 
ANOVA one-way performing the Bonferroni post-test (Instat software, version 3.0 
GraphPAD Software Inc., San Diego, CA) were used for the statistical analysis of the results. 
Significance was defined as a p value less than 0.05 (* p < 0.05; ** p < 0.01; *** p < 0.001). 
5. Results and discussion  
Tablet weight and dimensions data obtained for the formulations studied are reported in 
Table 4. 
 
PRODUCT 
Weight 
(g  SD) 
Thickness  
(mm  SD) 
Diameter 
(mm  SD) 
RF 0.4022 ± 0.0032 0.59 ± 0.006 0.97 ± 0.02 
MSF* 0.3995 ± 0.0037 0.58 ± 0.004 0.96 ± 0.01 
BF1* 0.4018 ± 0.0033 0.57 ± 0.002 0.91 ± 0.01 
BF2 0.4049 ± 0.0077 0.58 ± 0.005 0.96 ± 0.02 
BF3 0.4017 ± 0.0130 0.57 ± 0.006 0.95 ± 0.03 
BF4 0.4065 ± 0.0098 0.53 ± 0.002 1.02 ± 0.01 
BF5 0.4061 ± 0.0073 0.58 ± 0.003 0.92 ± 0.02 
BF6 0.7074 ± 0.0083 0.42 ± 0.003 1.33 ± 0.02 
BF7† 0.7063 ± 0.0075 0.42 ± 0.001 1.32 ± 0.02 
BF8 0.4044 ± 0.0068 0.46 ± 0.003 1.12 ± 0.03 
* a fracture line appears along the tablets diameter; †visible lamination with different coloration along 
the thickness. 
Table 4. Weight and shape size of tablets  
In detail, all the tablets have the same shape and each tablet has a weight of about 400 mg, 
except BF6 and BF7 that are heavier reaching a weight of about 700 mg. As far as the visual 
inspection is concerned, BF1 and BF8 show a fracture line along the tablets diameter as well 
as a different appearance along thickness of BF7 tablets was observed, suggesting 
lamination due to compression steps (Carstensen et al., 1985).  
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From dissolution data analysis it is possible to note that, apart from BF8 representing the 
lower amount released (6.0 mg, corresponding to the 6% after 1 h), the % of release for the 
formulations was between 16.1% and 23.0% (Figure 1). 
 
Fig. 1. Dissolution profiles of the various tablets at pH 6.8 (CV%<5). 
Such differences, that our adopted experimental conditions in the absence of sink-conditions 
were able to blow up, were attributed to formulation differences and/or manufacturing 
procedures. For this reason, to better explain the dissolution profile, saturation 
concentrations obtained from solubility studies in the presence of the various auxiliary 
substances were also adopted. They are shown in Figure 2. 
 
Fig. 2. Apparent solubility of NIM in the presence of tablet excipients (mean ± SD). The 
apparent solubility of NIM RS alone is indicated by the dotted line. Statistical significance 
with respect to NIM RS are also indicated.  
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NIM RS has the lowest Sapp (19.47 µg/mL) while for BF2 an increment of Sapp value near 30% 
(24.97 µg/mL) was obtained. With respect to NIM value, statistically significant increase in 
Sapp was obtained in all cases (p < 0.001, except than NIM vs. BF7 and NIM vs. BF4, for 
which p < 0.01 and p < 0.05 were observed, respectively). 
These data suggested us to use Sapp value of each formulation as normalization factor for 
each dissolution evaluation, instead of that of NIM solubility. Results are depicted in Figure 
3, from which it appears that also in this case BF8 is not able to reach the 30% of dissolution. 
 
Fig. 3. Dissolution profiles of the various tablets at pH 6.8 as obtained with respect to 
apparent solubility (CV%<5). 
As concerns BF4 its profile remains below all other curves. On the contrary, for BF1, after 1h 
is appreciable the achievement of 100%; such a result were not obtained by the other 
formulations, except than for RF. 
The simplest model to represent a dissolution of a BCS II drug is a first-order model, with a 
dissolution rate proportional to the difference between the apparent solubility of drug and 
the drug concentration in the liquid phase. Such a model, along with others, has been 
applied with DDSolver Software and the obtained results are shown in Table 5. 
The corresponding correlation coefficients, R2, in most of the adopted equations gave results 
higher than 0.97, and in all these cases the worst result is obtained in the description of the 
dissolution of the BF8 formulation. 
On the other hand, for Higuchi (R2<0.97, except than for BF8), Baker-Lonsdale (R2<0.97, 
except than for BF8), Quadratic (R2<0.90), Logistic3 (R2<0.97), Gompertz 3 and 4 (R2<0.95) 
models, the mathematical description often did not appear to be entirely sufficient. 
Moreover, for both Hixson-Crowell and Hopfenberg models, the mathematical fitting 
cannot be considered acceptable (R2<0.61). 
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Best-fit values RF MSF BF1 BF2 BF3 BF4 BF5 BF6 BF7 BF8 
Dissolution 
model 
          
First-order with 
Fmax 
          
k1 0.144 0.129 0.115 0.170 0.251 0.144 0.111 0.100 0.106 0.067 
Fmax 22.374 18.130 21.344 20.541 18.071 15.708 18.970 20.125 20.334 6.195 
R2 0.9855 0.9797 0.9942 0.9914 0.9860 0.9786 0.9846 0.9933 0.9921 0.9708 
Higuchi           
kH 3.626 2.925 3.376 3.218 3.113 2.573 2.989 3.115 3.176 0.881 
R2 0.9274 0.9427 0.9496 0.9597 0.8429 0.9315 0.9551 0.9647 0.9581 0.9854 
Korsmeyer-
Peppas 
          
kKP 9.864 7.264 7.596 6.819 11.787 6.858 6.651 6.233 6.738 1.192 
N 0.219 0.242 0.271 0.288 0.119 0.222 0.274 0.304 0.287 0.415 
R2 0.9931 0.9949 0.9839 0.9887 0.9939 0.9957 0.9902 0.9870 0.9863 0.9793 
Hixson-Crowell           
kHC 1.96·10-3 1.53·10-3 1.80·10-3 1.71·10-3 1.60·10-3 1.32·10-3 1.58·10-3 1.66·10-3 1.69·10-3 4.45·10-4 
R2 -0.0173 0.0746 0.1949 0.2647 -0.5867 -0.0293 0.2054 0.3204 0.2582 0.6021 
Hopfenberg           
kHC 3.06·10-5 1.15·10-5 7.04·10-5 1.91·10-5 2.31·10-5 2.50·10-5 2.09·10-5 1.72·10-5 1.27·10-5 2.27·10-5 
n 204.251 418.380 811.300 284.294 218.499 165.644 237.060 304.395 418.635 59.470 
R2 0.0338 0.1126 0.2371 0.3025 -0.5351 0.0046 0.2417 0.3555 0.2961 0.6082 
Baker-Lonsdale           
kBL 2.53·10-4 1.57·10-4 2.12·10-4 1.92·10-4 1.80·10-4 1.20·10-4 1.64·10-4 1.79·10-4 1.87·10-4 1.33·10-5 
R2 0.7892 0.8286 0.8655 0.8919 0.5211 0.7882 0.8737 0.9084 0.8888 0.9673 
Makoid-Banakar           
kMB 7.743 5.831 5.020 4.754 9.821 5.794 4.758 4.134 4.410 0.984 
n 0.350 0.360 0.491 0.478 0.221 0.313 0.451 0.520 0.511 0.513 
k 0.006 0.005 0.009 0.008 0.004 0.004 0.007 0.009 0.009 0.004 
R2 0.9991 0.9994 0.9981 0.9989 0.9984 0.9986 0.9992 0.9993 1.0000 0.9811 
Peppas-Sahlin 1           
k1 8.128 6.052 5.287 4.935 10.950 6.091 4.873 4.302 4.572 0.995 
k2 -0.708 -0.478 -0.320 -0.288 -1.608 -0.548 -0.304 -0.225 -0.252 -0.033 
m 0.418 0.426 0.528 0.523 0.310 0.381 0.506 0.555 0.550 0.547 
R2 0.9992 0.9994 0.9980 0.9990 0.9984 0.9987 0.9992 0.9992 1.0000 0.9813 
Peppas-Sahlin 2           
k1 6.639 5.075 5.671 5.209 6.605 4.605 4.948 4.908 5.168 1.087 
k2 -0.476 -0.344 -0.367 -0.318 -0.558 -0.325 -0.313 -0.287 -0.319 -0.033 
R2 0.9960 0.9973 0.9976 0.9988 0.9759 0.9931 0.9992 0.9981 0.9990 0.9809 
Quadratic           
k1 -1.64·10-4 -1.26·10-4 -1.45·10-4 -1.33·10-4 -1.58·10-4 -1.13·10-4 -1.26·10-4 -1.27·10-4 -1.33·10-4 -2.78·10-5 
k2 0.013 0.010 0.012 0.011 0.012 0.009 0.011 0.011 0.011 0.003 
R2 0.7173 0.7597 0.8227 0.8378 0.4934 0.7077 0.8284 0.8639 0.8539 0.9008 
Weibull 1           
ǂ 7.498 10.917 8.863 9.992 6.820 11.592 11.339 10.889 10.364 64.265 
ǃ 0.176 0.210 0.202 0.221 0.090 0.187 0.231 0.236 0.227 0.359 
Ti 3.717 2.900 4.198 4.011 3.910 3.058 3.257 3.960 3.845 2.533 
R2 0.9987 0.9978 0.9967 0.9990 0.9967 0.9984 0.9952 0.9977 0.9957 0.9818 
Weibull 2           
ǂ 9.851 13.529 13.054 14.618 8.026 14.282 14.921 16.069 14.795 84.457 
ǃ 0.244 0.264 0.299 0.317 0.131 0.239 0.299 0.333 0.316 0.425 
R2 0.9937 0.9954 0.9851 0.9898 0.9940 0.9960 0.9910 0.9881 0.9874 0.9795 
Weibull 3           
ǂ 3.270 3.537 5.410 5.303 1.703 3.067 4.589 6.038 5.551 9.326 
ǃ 0.567 0.522 0.749 0.692 0.472 0.479 0.624 0.732 0.719 0.626 
Fmax 24.458 20.970 22.296 22.119 19.086 18.408 20.968 21.461 21.608 8.499 
R2 0.9996 0.9992 0.9994 0.9997 0.9981 0.9989 0.9982 0.9998 0.9995 0.9818 
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Weibull 4           
ǂ 3.136 3.531 4.935 3.580 1.708 3.021 4.584 5.517 5.551 8.735 
ǃ 0.551 0.522 0.718 0.539 0.474 0.472 0.624 0.700 0.719 0.490 
Ti 0.208 0.000 0.338 1.726 0.000 0.103 0.000 0.357 0.000 1.577 
Fmax 24.559 20.980 22.387 23.231 19.074 18.482 20.980 21.597 21.608 11.250 
R2 0.9996 0.9992 0.9994 0.9999 0.9981 0.9989 0.9982 0.9998 0.9995 0.9820 
Logistic 1           
ǂ -2.261 -2.588 -2.563 -2.680 -2.026 -2.639 -2.696 -2.781 -2.693 -4.444 
ǃ 0.626 0.659 0.760 0.799 0.331 0.591 0.749 0.839 0.796 1.001 
R2 0.9942 0.9957 0.9861 0.9907 0.9942 0.9962 0.9916 0.9892 0.9884 0.9797 
Logistic 2           
ǂ -1.342 -1.411 -2.006 -1.945 -0.497 -1.244 -1.709 -2.091 -1.968 -2.546 
ǃ 1.805 1.490 2.399 2.128 1.786 1.414 1.778 2.215 2.156 1.635 
Fmax 27.070 24.666 24.318 24.700 20.109 21.295 24.443 24.070 24.293 10.810 
R2 0.9996 0.9990 0.9993 0.9999 0.9978 0.9989 0.9976 0.9997 0.9988 0.9821 
Logistic 3           
k 0.340 0.269 0.265 0.248 1.197 0.324 0.231 0.235 0.236 0.192 
ɣ 5.271 6.083 6.837 7.154 3.923 5.324 7.072 7.637 7.358 10.074 
Fmax 21.639 17.707 20.766 19.927 17.549 15.229 18.552 19.506 19.803 5.775 
R2 0.9285 0.9190 0.9489 0.9423 0.9699 0.9179 0.9287 0.9480 0.9433 0.9344 
Gompertz 1           
ǂ 2.462 2.776 2.806 2.932 2.176 2.797 2.919 3.050 2.944 4.713 
ǃ 0.307 0.297 0.361 0.372 0.155 0.255 0.339 0.385 0.369 0.305 
R2 0.9959 0.9971 0.9898 0.9939 0.9946 0.9973 0.9939 0.9929 0.9918 0.9815 
Gompertz 2           
ǂ 1.903 1.936 2.913 2.708 1.119 1.761 2.284 2.912 2.714 3.479 
ǃ 1.223 0.864 1.615 1.353 1.455 0.857 1.041 1.374 1.351 0.628 
Fmax 29.151 29.053 26.049 27.274 20.482 24.445 28.420 26.859 26.975 19.954 
R2 0.9995 0.9988 0.9991 0.9999 0.9977 0.9989 0.9971 0.9995 0.9983 0.9823 
Gompertz 3           
k 0.243 0.202 0.191 0.178 0.517 0.237 0.172 0.167 0.171 0.120 
ɣ 3.569 3.899 4.530 4.731 2.523 3.537 4.515 5.058 4.804 7.011 
Fmax 21.88 17.800 20.905 20.082 17.685 15.369 18.650 19.657 19.930 5.907 
R2 0.9560 0.9467 0.9705 0.9651 0.9739 0.9466 0.9538 0.9688 0.9656 0.9492 
Gompertz 4           
k 0.243 0.202 0.191 0.178 0.518 0.237 0.172 0.167 0.171 0.120 
ǃ 2.378 2.202 2.381 2.319 3.693 2.310 2.169 2.325 2.272 2.315 
Fmax 21.882 17.801 20.904 20.082 17.685 15.370 18.650 19.659 19.931 5.908 
R2 0.9560 0.9467 0.9705 0.9651 0.9739 0.9466 0.9538 0.9688 0.9656 0.9492 
Probit 1           
ǂ -1.337 -1.502 -1.500 -1.560 -1.199 -1.521 -1.562 -1.612 -1.566 -2.318 
ǃ 0.356 0.361 0.427 0.444 0.185 0.318 0.412 0.464 0.442 0.452 
R2 0.9949 0.9964 0.9877 0.9922 0.9944 0.9968 0.9927 0.9909 0.9900 0.9808 
Probit 2           
ǂ -0.830 -0.872 -1.256 -1.215 -0.279 -0.765 -1.065 -1.308 -1.234 -1.581 
ǃ 1.175 0.966 1.551 1.375 1.136 0.917 1.158 1.430 1.404 0.926 
Fmax 26.154 23.865 23.571 23.928 19.598 20.617 23.574 23.317 23.449 12.131 
R2 0.9996 0.9989 0.9993 0.9999 0.9978 0.9989 0.9975 0.9997 0.9988 0.9822 
Table 5. Parameters and determination coefficients of various dissolution models. 
Further investigation may be done by going to compare the Sapp experimental data with 
those determined using some equations, which allows to calculate a value of Fmax (Figure 4). 
As it is possible to observe, no model is able to estimate properly the experimental Sapp 
parameter of the various preparations, except than the Weibull functions. In detail, either 
under- or overestimations have been observed, with the model Gompertz 2 that provides a 
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value always greater than the others. As for BF8, the non-sink conditions allow to show a 
significant extension of time to reach the maximum value of the dynamic solubility. 
 
Fig. 4. Comparison of experimental Sapp and calculated Fmax derived from mathematical 
fitting. 
6. Conclusion 
A continuous know-how improvement of both formulation and manufacturing process 
parameters with respect to drug release modalities is a basic aspect of the quality framework 
for pharmaceutical products. Such features become of paramount relevance for generic 
manufacturers in the case of formulation of insoluble or poorly soluble drugs, where 
dissolution represents the most critical factor. In fact, both the excipients used as well as the 
manufacture parameters are of great importance to solid dosage form performance. The in 
vivo solubility behaviour is dependent on many factors and it cannot be fully obtained in 
vitro. Regardless the worth of “sink conditions” in the achievement of bio-relevant 
dissolution methods for poorly water-soluble drugs, an approach more suitable as 
developmental tool as well as for batch quality control in both pre-formulation and 
formulation stages is of great interest. 
For such purposes, various commercial Immediate Release tablets containing a drug, 
namely NIM, differently banned, used and prescribed in the various European Countries 
have been chosen. NIM apparent solubilities and dissolution patterns as obtained in “non-
sink conditions”, i.e. in a system where the solute is present for more than 15% of its 
maximum solubility, have been studied. “Non-sink conditions” represented a very 
discriminating dissolution conditions, acting as a sort of magnifier lens for an in-depth 
evaluation of the dissolution phenomenology, useful since the preformulation stages.  
Eventually, in such a situation of drug saturation during tablet dissolution the mathematical 
approaches far developed usually are not capable of describing the overall profile 
peculiarity. 
For this reason, a more complex dissolution scheme based on the ash layer diffusion control 
by shrinking core model is  under study.  
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